| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC) |
| 26 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 21 Aug 2026 | EFFECT |
| 18 Aug 2026 |
Form 4: Brady Kelly, See Remarks
Received 181 shares by exercise or conversion · Sold 64 shares ($291) |
| 18 Aug 2026 |
Form 4: Shaff Eric D., Director
Received 722 shares by exercise or conversion · Sold 263 shares ($1.2K) |
| 18 Aug 2026 |
Form 4: Henn Matthew R, See Remarks
Received 238 shares by exercise or conversion · Sold 81 shares ($369) |
| 18 Aug 2026 |
Form 4: DesRosier Thomas, See Remarks
Received 245 shares by exercise or conversion · Sold 82 shares ($373) |
| 13 Aug 2026 | S-3 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS |
| 04 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
This STOCK ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of July 31, 2026 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and BMR-SIDNEY RESEARCH CAMPUS LLC, a Delaware limited liabili... |
| 04 Aug 2026 | 424B5 |
| 10 Jul 2026 |
Form 4: Graves Kurt, Director
Granted 6,500 Stock Option (right to buy) |
| 10 Jul 2026 |
Form 4: Kender Richard N, Director
Granted 50,000 Stock Option (right to buy) |
| 10 Jul 2026 |
Form 4: Fraser Claire, Director
Granted 6,500 Stock Option (right to buy) |
| 10 Jul 2026 |
Form 4: Dere Willard H, Director
Granted 6,500 Stock Option (right to buy) |
| 10 Jul 2026 |
Form 4: Ausiello Dennis A, Director
Granted 6,500 Stock Option (right to buy) |
| 10 Jul 2026 |
Form 4: Berenson Stephen, Director
Granted 6,500 Stock Option (right to buy) |
| 10 Jul 2026 |
Form 4: DesRosier Thomas, See Remarks
Granted 7,500 Stock Option (right to buy) |
Loading...